Cardiac and vascular toxicities of angiogenesis inhibitors: The other side of the coin.

@article{Alameddine2015CardiacAV,
  title={Cardiac and vascular toxicities of angiogenesis inhibitors: The other side of the coin.},
  author={Raafat S Alameddine and Ahmad Sharif Yakan and Hadi Skouri and Deborah A Mukherji and Sally N. Temraz and Ali Shamseddine},
  journal={Critical reviews in oncology/hematology},
  year={2015},
  volume={96 2},
  pages={195-205}
}
Angiogenesis is one of the best-described tumor hallmarks. Targeting angiogenesis is becoming a successful strategy to suppress cancer growth. Vascular endothelial growth factor (VEGF), the fulcrum of angiogenesis, contributes to vascular and cardiac homeostasis. Angiogenesis inhibitors classically associated with vascular side effects are increasingly… CONTINUE READING